Form D · Pharmaceuticals

Acer Therapeutics Inc.

Cambridge, MA · CIK 0001638234

Offering snapshot reported Oct 4, 2017 · SEC filing

Reported sold: $15.7M
Investors reported: 10
Minimum accepted: $0
First sale: Sep 19, 2017

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 4, 2017	Initial	$15,674,384	No comparison	10	SEC filing
Apr 5, 2017	Initial	$3,125,000	No comparison	4	SEC filing
May 6, 2016	Initial	$8,149,999	No comparison	6	SEC filing
May 6, 2016	Amendment	$8,149,999	$0vs May 6, 2016	6	SEC filing
Apr 2, 2015	Initial	$2,100,000	No comparison	2	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $1.1M (estimated)
Finders' fees: $67.5K (estimated)
Form D file number: 021-295986

The sales commission and finders' fees reflect amounts described in an invoice provided by Piper Jaffray & Co. The total amount payable remains in dispute.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Piper Jaffray & Co.	665

Source: Form D, filed Oct 4, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Stephen Aselage	Director
Hubert Birner	Director
John Dunn	Director
Cynthia Lavoie	Director
Luc Marengere	Director
Harry S. Palmin	Executive
Christopher Schelling	Director, Executive
Robert Steiner	Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

222 Third Street, Suite 2240
Cambridge, MA, 02142